Capital Impact Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Capital Impact Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,230	Closed	-$1.4M	–	130
2019 Q1	$1.4M	Hold	10,230	–	–	0.62%	93
2018 Q4	$1.4M	Buy	10,230 +3,430	+50%	+$579K	0.6%	96
2018 Q3	$1.74M	Buy	+6,800	New	+$1.88M	0.6%	93
2016 Q3	–	Sell	-777	Closed	-$78K	–	221
2016 Q2	$78K	Hold	777	–	–	0.04%	219
2016 Q1	$104K	Hold	777	–	–	0.05%	219
2015 Q4	$155K	Hold	777	–	–	0.07%	250
2015 Q3	$123K	Hold	777	–	–	0.06%	252
2015 Q2	$317K	Hold	777	–	–	0.14%	230
2015 Q1	$357K	Buy	777 +522	+205%	+$225K	0.16%	224
2014 Q4	$143K	Hold	255	–	–	0.07%	181
2014 Q3	$133	Hold	255	–	–	﹤0.01%	175
2014 Q2	$178K	Buy	+255	New	+$119K	0.13%	111

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Capital Impact Advisors's KPTI Position: Q2 2019 in Review

Capital Impact Advisors sold out of Karyopharm Therapeutics (KPTI) in Q2 2019, closing a stake of 10,230 shares — an estimated $1.4M sold.

Capital Impact Advisors first reported a position in KPTI in Q2 2014 and held it in 12 quarters. The position peaked at $1.74M in Q3 2018. 103 funds tracked by Wall St. Rank hold KPTI as of Q2 2019.

Capital Impact Advisors reported no remaining Karyopharm Therapeutics position as of Q2 2019 after selling out during the quarter.
Capital Impact Advisors sold 10,230 Karyopharm Therapeutics shares in Q2 2019, an estimated $1.4M.
Capital Impact Advisors first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 12 quarters.
Capital Impact Advisors's Karyopharm Therapeutics position peaked at $1.74M in Q3 2018.
103 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2019.

Based on Capital Impact Advisors's 13F filing for Q2 2019, filed 19 Jul 2019.